Must Asset Management has publicly opposed PharmaResearch's planned equity spin-off, warning it primarily benefits major shareholders and could worsen corporate governance, as shares plunged 17% and market cap fell by 1 trillion won ($725 million).
#YonhapInfomax #PharmaResearch #MustAssetManagement #EquitySpinOff #ShareholderGovernance #MarketCapitalizationDrop #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=67665